Aethlon Medical (AEMD)
(Delayed Data from NSDQ)
$1.18 USD
-0.07 (-5.67%)
Updated May 9, 2024 02:49 PM ET
After-Market: $1.25 +0.07 (6.01%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AEMD 1.18 -0.07(-5.67%)
Will AEMD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AEMD based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AEMD
Aethlon Medical files to sell common stock, warrants
Aethlon Medical files to sell common stock, warrants, no amount given
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)
Aethlon Medical price target lowered by $13 at H.C. Wainwright, here's why
Aethlon Medical announces TA with Santersus